the results of this randomized cross-over study indicate that , in the dosage/schedule used , lorazepam is a significantly superior premedicant than is either oxazepam or methylprednisolone in alleviating the distress of cytotoxic-induced emesis in patients receiving cisplatin-containing chemotherapy .
C0024002
lorazepam
C0042963
emesis